Halofuginone

In response to the prevention and control demands for poultry coccidiosis and parasitic infections in ruminants such as cattle and sheep, halofuginone, a broad-spectrum quinazolinone antiparasitic drug, plays a critical clinical value. Its mechanism of action is to specifically inhibit the glycolysis and nucleic acid synthesis of parasites, and it has significant killing activity against various Eimeria species such as Eimeria tenella, Eimeria necatrix, and Eimeria acervulina, as well as Theileria and Cryptosporidium. In the animal husbandry and breeding field, it is mainly used for the prevention of poultry coccidiosis, and can also be used as a veterinary prescription drug to treat parasitic infections in ruminants. It is an important antiparasitic drug option in the healthy breeding system for livestock and poultry.

At present, the global market size of veterinary antiparasitic API is growing steadily. The market size of the coccidiosis prevention and control related segment is approximately USD 1.2 billion, with a compound annual growth rate maintained at around 4.2%. With the advantages of low drug resistance and short withdrawal period, the market share of halofuginone continues to rise. In terms of the competitive landscape, overseas enterprises still occupy the major share of the mid-to-high-end market at present. With process optimization, domestic enterprises have gradually highlighted their cost advantages, and China has become one of the core supply regions for halofuginone API in the world. In 2023, the export volume of domestic halofuginone API increased by 18% year-on-year.

The original research enterprise of halofuginone is Hoechst AG (Germany), which was later merged into Sanofi Group. The original research trade name is "Stenorol". Its core compound patent expired globally in 2001. The main dosage form of the original research product is 0.6% halofuginone premix, which is a veterinary reference preparation approved in the mainstream global markets, and has been included in the FDA Reference Listed Drugs for Animal Products. In China, at present, 2 enterprises have obtained CDE registration numbers (status A) for their halofuginone API, and the halofuginone premixes of multiple enterprises have been approved for marketing, which can meet the drug demand of the domestic breeding market. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of halofuginone impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use demands in various links such as API R&D, quality research, and registration declaration.